Source: Journal of Viral Hepatitis, by Nomin Ariungerel; Khaliunaa Otgonbaatar; Saruul Enkhjargal; Ulziigerel Erdembileg; Sumiya Byambabaatar; Badmaarag Munkhjin; Tuul Tsagaantsooj; Sanjaasuren Enkhtaivan; Byambasuren Ochirsum; Purevjargal Bat‐Ulzii; Enkhnomin Ochirbat; Naranjargal Dashdorj; Odgerel Oidovsambuu (August 28, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- A chemiluminescence ELISA quantified anti-HDV antibodies in 399 serum samples and detected pure standards down to 0.5 ng/mL.
- Anti-HDV antibody levels did not significantly correlate with HDV-RNA, HBV-DNA, ALT, or AST in chronic HDV infection.
- Antibody concentrations did not track viral load or liver-injury markers, so they cannot serve as direct proxies for those measures.
Researchers in Mongolia have developed a quantitative blood test for antibodies against hepatitis delta virus, or HDV, and found that those antibody levels did not track with the amount of virus in patients' blood. The chemiluminescence-based enzyme-linked immunosorbent assay, known as an ELISA, measured anti-HDV antibodies across 399 serum samples, including 199 samples already identified as antibody-positive and 200 healthy controls. In the study cohort, the test reported 100% sensitivity and 100% specificity and could detect purified antibody standards down to 0.5 nanograms per milliliter. The team then compared antibody concentrations with HDV ribonucleic acid, or HDV-RNA, a measure of circulating virus, as well as hepatitis B virus DNA and liver-enzyme measurements. Anti-HDV antibody levels showed no significant association with HDV-RNA, alanine aminotransferase, or ALT, and aspartate aminotransferase, or AST. That result suggests that the measurable antibody response in chronic HDV infection captures a different part of the disease than viral burden or these common indicators of liver-cell injury. The study did identify differences by sex in antibody levels and ALT, while HDV-RNA, hepatitis B virus DNA, and AST did not significantly differ between male and female participants. By turning a commonly qualitative HDV antibody result into a numerical measurement, the work creates a tool for examining immune responses to a virus that causes particularly severe liver disease.
A virus that depends on hepatitis B
HDV is an unusual, small RNA virus because it cannot propagate on its own. It requires hepatitis B virus, or HBV, to complete its life cycle, meaning HDV infection occurs alongside HBV infection rather than independently.
HDV and HBV co-infection or HDV superinfection in a person with chronic HBV can accelerate liver fibrosis, the buildup of scar tissue in the liver. It is also associated with higher risks of cirrhosis, hepatocellular carcinoma, a primary liver cancer, and liver-related death, making better ways to characterize the infection important.
Turning an antibody screen into a measurement
Clinical testing for HDV commonly begins by looking qualitatively for anti-HDV antibodies, essentially reporting whether antibodies are present or absent. That approach can identify exposure or infection-related immune activity, but it cannot show how much antibody is circulating in a patient's serum.
The Mongolian team designed a quantitative ELISA that uses chemiluminescence, light produced by a chemical reaction, to generate a readout. Like judging the brightness of a lamp rather than simply checking whether it is switched on, the method is intended to translate an antibody signal into a concentration.
In validation experiments, the assay quantified anti-HDV antibodies linearly and detected pure standards at concentrations as low as 0.5 ng/mL. Its reported sensitivity and specificity were both 100% in the tested set, meaning it correctly identified the positive and healthy-control samples used for this evaluation.
What 399 serum samples revealed
The researchers tested 399 serum samples in total: 199 from people positive for HDV antibodies and 200 from healthy controls. Among the antibody-positive group, the overall mean anti-HDV antibody concentration was 67,622 ng/mL.
Mean concentrations were 70,883 ng/mL in males and 64,043 ng/mL in females. Although the tested population was heterogeneous, the antibody levels followed a normal distribution, a familiar bell-shaped pattern in which most measurements cluster around an average and fewer fall at the high or low extremes.
Antibodies did not mirror viral load
The central finding emerged when the investigators compared antibody concentrations with HDV-RNA. HDV-RNA measures genetic material from the virus in serum and is used as an indicator of viral load, or how much virus is circulating in the blood at a given time.
Patients grouped by high versus low HDV-RNA showed no significant difference in anti-HDV antibody levels. Correlation analyses likewise found no significant relationship between antibodies and HDV-RNA, indicating that a higher measurable antibody concentration did not correspond consistently to either more or less circulating HDV.
This distinction matters because antibodies and viral RNA reflect different biological processes. Antibodies are proteins produced by the humoral immune system, the arm of immunity that circulates through blood and other body fluids, while viral RNA records the presence of the virus itself.
Liver enzymes told a separate story
The investigators also examined ALT and AST, enzymes that can rise in blood when liver cells are injured. Neither enzyme showed a significant correlation with anti-HDV antibody levels, so the quantitative antibody result did not act as a direct stand-in for these liver-injury markers.
Sex-based comparisons did reveal statistically significant differences in anti-HDV antibody concentration and ALT, with reported p values of 0.0128 and 0.0006, respectively. By contrast, the groups did not significantly differ in HDV-RNA, HBV-DNA, or AST, a pattern that points to biological variation worth examining further without establishing its cause.
Why This Matters
A numeric anti-HDV assay could give researchers a more precise way to study the immune response during chronic HDV infection. The study's results also caution against interpreting an antibody amount as a proxy for viral load or for liver-enzyme levels, even though all of these measurements come from the same blood sample.
That separation could be useful in studies that seek to understand why people with chronic HDV infection differ in disease course. Rather than treating antibodies as a single summary of disease activity, investigators may be able to evaluate immune response, viral replication, and liver injury as related but distinct measurements.
Next questions for quantitative HDV testing
The assay now provides a basis for following anti-HDV antibody concentrations with greater resolution than a positive-or-negative test can offer. Future work can examine how these levels change over time and how they relate to other aspects of chronic infection, while retaining the study's key observation: in this cohort, serum anti-HDV antibody levels were independent of HDV-RNA and the liver markers measured.